<DOC>
	<DOCNO>NCT00638742</DOCNO>
	<brief_summary>To evaluate steady-state systemic plasma concentration latanoprost acid follow administration latanoprost 0.005 % ( 1.5 ug ) pediatric adult subject glaucoma ocular hypertension .</brief_summary>
	<brief_title>A Phase 1 , Open-Label Study Latanoprost Acid Plasma Concentrations Pediatric Adult Glaucoma Patients Treated With Latanoprost .</brief_title>
	<detailed_description>Pharmacokinetics Safety</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>This study enroll pediatric adult subject glaucoma ocular hypertension receive treatment latanoprost either one eye least two week . The pediatric subject group age ( 0 &lt; 3 year , 3 &lt; 12 year , 12 18 year ) . Ocular inflammation/infection history ocular inflammation/infection within 3 month prior screen visit . History ocular trauma surgery either eye within 14days screen visit . Use continuous wear contact lenses .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Latanoprost Pediatrics Pharmacokinetics Safety</keyword>
</DOC>